Items Tagged ‘precision cancer medicines’

May 7, 2018

FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma

By

CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.1 About Melanoma  Stage III melanoma includes cancers of any thickness that have spread to the […]

View full entry

Tags: adjuvant treatment, BRAF V600E, dabrafenib, mekinist, Melanoma, News, precision cancer medicines, stage III, tafinlar, trametinib, V600K mutations


April 3, 2018

Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder) cancer who were previously treated with checkpoint inhibitors. Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a […]

View full entry

Tags: Bladder Cancer, checkpoint inhibitors, Enfortumab vedotin, News, PD-1, precision cancer medicines